Abstract
The enediyne antibiotics, the potent anticancer agents that contain diyne-ene functional groups, are appreciated for their novel molecular architecture, their remarkable biological activity and their fascinating mechanism of action. Their anticancer activity is apparently due to their ability to damage DNA through radical-mediated hydrogen abstraction. The enediyne antibiotics show markedly cytotoxicities against cancers in vitro and in vivo. Lidamycin is a member of the enediyne anticancer antibiotic family. This review examines lidamycin with particular emphasis on the discovery, the biological properties and its structure-activity relationships. In addition, the possible mechanisms of action of lidamycin are described. Recent progress, particularly in the areas of biosynthesis, and immunoconjugates are highlighted. Finally, the pharmacological applications of lidamycin in cancer therapy and its potential use as anticancer agents are also discussed.
Keywords: Lidamycin, Anticancer antibiotic, Enediyne, DNA damage, Cell cycle arrest, Apoptosis, Immunoconjugate, Cancer therapy
Anti-Cancer Agents in Medicinal Chemistry
Title: Enediyne Anticancer Antibiotic Lidamycin: Chemistry, Biology and Pharmacology
Volume: 8 Issue: 2
Author(s): Rong-guang Shao and Yong-su Zhen
Affiliation:
Keywords: Lidamycin, Anticancer antibiotic, Enediyne, DNA damage, Cell cycle arrest, Apoptosis, Immunoconjugate, Cancer therapy
Abstract: The enediyne antibiotics, the potent anticancer agents that contain diyne-ene functional groups, are appreciated for their novel molecular architecture, their remarkable biological activity and their fascinating mechanism of action. Their anticancer activity is apparently due to their ability to damage DNA through radical-mediated hydrogen abstraction. The enediyne antibiotics show markedly cytotoxicities against cancers in vitro and in vivo. Lidamycin is a member of the enediyne anticancer antibiotic family. This review examines lidamycin with particular emphasis on the discovery, the biological properties and its structure-activity relationships. In addition, the possible mechanisms of action of lidamycin are described. Recent progress, particularly in the areas of biosynthesis, and immunoconjugates are highlighted. Finally, the pharmacological applications of lidamycin in cancer therapy and its potential use as anticancer agents are also discussed.
Export Options
About this article
Cite this article as:
Shao Rong-guang and Zhen Yong-su, Enediyne Anticancer Antibiotic Lidamycin: Chemistry, Biology and Pharmacology, Anti-Cancer Agents in Medicinal Chemistry 2008; 8 (2) . https://dx.doi.org/10.2174/187152008783497055
DOI https://dx.doi.org/10.2174/187152008783497055 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Discovery of Lead compounds targeting transcriptional regulation
Transcriptional regulation plays key physiological functions in body growth and development. Transcriptional dysregulation is one of important biomarkers of tumor genesis and progression, which is involved in regulating tumor cell processes such as cell proliferation, differentiation, and apoptosis. Additionally, it plays a pivotal role in angiogenesis and promotes tumor metastasis ...read more
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Innovative targets in medicinal chemistry
Medicinal chemistry continuously evolves in response to emerging healthcare needs and advancements in scientific understanding. This special issue explores the current landscape of innovative targets in medicinal chemistry, highlighting the quest for novel therapeutic avenues. From traditional drug targets such as enzymes and receptors to emerging targets like protein-protein interactions ...read more
Rechallenge Therapy in different types of cancer
Cancer is responsible for approximately 8 million deaths annually all worldwide. The Global burden of cancer (GLOBOCAN) 2020 reported 19.3 million new cases of cancer, which is projected to increase to 28.4 million by 2040.In the future , female breast cancer will be the most common cancer (11.7%) followed by ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Collateral Damage Control in Cancer Therapy: Defining the Stem Identity in Gliomas
Current Pharmaceutical Design Preclinical and Clinical Studies of Chidamide (CS055/HBI-8000), An Orally Available Subtype-selective HDAC Inhibitor for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Redox Control of Cardiovascular Homeostasis by Angiotensin II
Current Pharmaceutical Design Cellular Senescence in the Development and Treatment of Cancer
Current Pharmaceutical Design MicroRNAs Determining Carcinogenesis by Regulating Oncogenes and Tumor Suppressor Genes During Cell Cycle
MicroRNA Cyclin-Dependent Kinase Inhibitors as Anticancer Drugs
Current Drug Targets RNA Interference as Therapeutics for Hepatocellular Carcinoma
Recent Patents on Anti-Cancer Drug Discovery A Novel Relationship for Schizophrenia, Bipolar and Major Depressive Disorder Part 6: A Hint from Chromosome 6 High Density Association Screen
Current Molecular Medicine Studies on Anticancer Activities of Lactoferrin and Lactoferricin
Current Protein & Peptide Science Chalcones Incorporated Pyrazole Ring Inhibit Proliferation, Cell Cycle Progression, Angiogenesis and Induce Apoptosis of MCF7 Cell Line
Anti-Cancer Agents in Medicinal Chemistry Overview of PCTK3/CDK18: A Cyclin-Dependent Kinase Involved in Specific Functions in Post-Mitotic Cells
Current Medicinal Chemistry The ALK Gene, An Attractive Target for Inhibitor Development
Current Topics in Medicinal Chemistry TGFß, a Potent Regulator of Tumor Microenvironment and Host Immune Response, Implication for Therapy
Current Molecular Medicine Berberine as a Promising Safe Anti-Cancer Agent- Is there a Role for Mitochondria?
Current Drug Targets Past, Present, and Future of Targeting Ras for Cancer Therapies
Mini-Reviews in Medicinal Chemistry Myc - What We have Learned from Flies
Current Drug Targets Viral Vectors for Cancer Gene Therapy: Viral Dissemination and Tumor Targeting
Current Gene Therapy An Update on Molecular Research of Pancreatic Adenocarcinoma
Anti-Cancer Agents in Medicinal Chemistry Quinoxalinone as a Privileged Platform in Drug Development
Mini-Reviews in Medicinal Chemistry “Virostatics” as a Potential New Class of HIV Drugs
Current Pharmaceutical Design